MAP2K7 and non-small cell lung carcinoma: In vitro and in vivo, CDK4/6 inhibitor (palbociclib) showed combination effects with MEK inhibitor in RAS‐driven NSCLC cell lines, including increased growth inhibition and the population of cells in G1 phase, and overcome the resistant to the MEK inhibitor [268, 269].